Loading

Plasma Carbonic Anhydrase II Level is Increased in Children with Sickle Cell Anaemia Compared to Healthy Controls

Research Article | Open Access | Volume 1 | Issue 3

  • 1. Department of Biochemistry, School of pure and applied sciences, Kenyatta University, Kenya
  • 2. Department of Medical physiology, School of medicine, Kenyatta University, Kenya
+ Show More - Show Less
Corresponding Authors
Charlote Midiwo, Department of Biochemistry, School of pure and applied sciences, Kenyatta University, P.O.Box 30003-00100, Nairobi, Kenya, Tel: 254-0728333082.
Abstract

Introduction: Erythrocyte carbonic anhydrase II (CAII) the bicarbonate supplier causes acidification of the red blood cell hence triggering the dissociation of oxygen from oxyhemoglobin. Mutant hemoglobin S favors sickling in this hypoxic state.

Objective: The purpose of this study was to determine the plasma levels of CA II in known cases of sickle cell disease and to compare them with gender matched healthy controls.

Materials and methods: 40 participants were enrolled for the present case-controlled study with age ranging from 6 months to 12 years. After assessment of complete blood count, sickling and hemoglobin electrophoresis, CAII levels were determined by enzyme linked immunosorbent assay (ELISA).

Result: The mean carbonic anhydrase levels were significantly elevated in children who suffered from sickle cell disease compared to healthy controls (p=0.0001). Carbonic anhydrase II mean levels was significantly enhanced in children who suffered from the clinical complications of sickle cell disease compared to healthy controls (p=0.0001).

Conclusion: Plasma CA II levels were significantly increased in children with sickle cell anemia. The mean carbonic anhydrase II levels were elevated in children with clinical complications of sickle cell anemia.

Keywords

•    Carbonic anhydrase
•    Erythrocyte
•    Hemoglobin S
•    Hypoxia
•    Polymerization

Citation

Midiwo C, Okun D, Gwer S, Ogweno G (2017) Plasma Carbonic Anhydrase II Level is Increased in Children with Sickle Cell Anaemia Compared to Healthy Controls. Arch Paediatr Dev Pathol 1(3): 1013.

ABBREVIATIONS

CA: Carbonic Anhydrase; Hb: Hemoglobin; ELISA: Enzyme Linked Immunosorbent Assay; SCD: Sickle Cell Disease; EDTA: Ethylene Diamine TetraAceticAcid; RBC: Red Blood Cell; WBC: White Blood Cell; SD: Standard Deviation; MCV: Mean Cell Volume; HCT: Hematocrits; MCH: Mean Cell Hemoglobin; MCHC: Mean Cell Hemoglobin Concentration; G6PDH: Glucose 6 Phosphate Dehydrogenase; Plts: Platelets

INTRODUCTION

SCD is an umbrella term of group of autosomal recessive genetic disorders characterized by mutation on the β subunit of the globin chain of hemoglobin within the red blood cells [1]. The disease has been associated with an abnormal variant of hemoglobin (HbS) which causes reversible polymerization of hemoglobin and red blood cell sickling on exposure to low oxygen concentration [2]. Polymerization distorts erythrocyte structure into a variety of sickled shape, damaging the erythrocyte membrane and ultimately causing hemolysis with attendant anemia, ischemia, and infarction and organ dysfunction [1]. SCD complications include chronic anemia, acute chest syndrome, stroke, splenic and renal dysfunction, pain crisis and susceptibility to bacterial infections [3].

In erythrocytes, ubiquitous zinc containing metalloenzyme carbonic anhydrase has been known to catalyze the reversible hydration of CO2 to H2 CO3 . Carbonic acid (CA) dissociates spontaneously into H and HCO3- ions. Bicarbonate ions are transferred out of the red blood cells by the band 3 in exchange for chloride ions. This leads to the conversion of a weak acid carbonic acid to a strong acid HCl and renders the pH of the red blood cell acidic hence triggering the dissociation of oxygen from oxyhemoglobin [4]. Mutant HbS favors the occurrence of sickling in this hypoxic state [5]. Thus by extension, enhanced CA II expression promotes sickling of SCD status and the related complications. The first evidence about a factor in red blood cell necessary for the sickling process was from the work of [6]. Following this line of argument [7,8] reported a potential role of CA on the sickling process, in vitro mediated by its effect on the oxygen dissociation curve and erythrocyte membrane.

Little variation in the level of CA isoenzymes has been observed with healthy human population; however a wide variation occurs in various disease status [9]. Two isoenzymes of CA are widely distributed in the erythrocytes and since the enzyme in blood is contained wholly within the erythrocytes, it is apparent that CA in blood might be abnormal in anemia [10]. Mondrup [11], illustrated the CA isoenzyme B in erythrocyte of subjects with different types of anemia and that the isoenzyme contributes differently in various anemias. Based on this fact that different types of anemia vary in regard to carbonic anhydrase activity [10,12], investigated the blood CA in anemic blood and illustrated high levels of CA in patients with sickle cell disease and leukemia. We considered it desirable to study this matter again using a different technique. The objective of this study was to relate CA levels in patients with sickle cell disease compared to healthy controls in order to explore its use as a surrogate marker for the progression of clinical complications and treatment interventions.

ETHICAL CONSIDERATION

The study was approved by the Ethical Committee of the institution review board (GCH/ERB/VOLXV/38). Written informed consent was obtained from the parents of all participants before enrollment.

MATERIALS AND METHODS

This case-controlled study was carried out in a tertiary hematology clinic. We included children with history of sickle cell disease between the ages of 6 months to 12 years with a confirmed diagnosis of sickle cell disease as determined by Hb electrophoresis. We also recruited controls: normal children with confirmed HbAA phenotype matched according to gender and age. We excluded patients who had: history of blood transfusion in the past 3 months, diagnosed with other hemoglobinopathies and enzymopathies. A total of 40 participants (28 males and 12 females) were enrolled for the study with age ranging from 2 months to 12 years. 20 SCD patients (14 men and 6 Females) and 20 control individual, who visited the surgical clinic for elective hernia repair, were randomly selected to match the SCD patients with regard to demographical data such as gender and age.

Blood was obtained from children with SCD and healthy controls into Ethylene Diamine Tetra Acetic Acid (EDTA) anticoagulant bottles and labeled with the study number of participants. Full hemogram was done using sysmex XT-2000? (sysmex corporation kobe Japan). As a primary screening procedure, sickling test was also carried out on the same day of collection according to the method [13]. The remaining blood was centrifuged for 15 minutes at a speed of 1000g using Thermo Scientific CL 10 centrifuge to separate red blood cells and plasma. Plasma was reserved in labeled containers with study numbers and stored at 20º C for analysis of carbonic anhydrase while the remaining red blood pellets were vortexed for 5 seconds and stored between 2° and 8° C for up to 7 days for Hb electrophoresis. The hemoglobin phenotypes of all patients and controls were confirmed using an automated capillary electrophoresis MINICAP system according to the method [13].

Carbonic anhydrase II levels were determined by a 96 well microplate ELISA kit purchased from ELAB science biotechnology precoated with CAII antibody according to [14]. All reagents, working standard and samples were prepared; 100μl of standard or sample were added to each well. The liquid in each well was removed without washing. 100μl of Biotin-antibody was added to each well and incubated for 1 hour at 37º C after which each well was aspired and washed 3 times with a wash buffer (200μl). After the last wash, any remaining wash buffer was removed by aspirating. 100μl of HRP-Avidin was added to each well and incubated for 1 hour at 37º C after which each well was aspirated and washed five times. 90μL of TBM substrate was added to each well and incubated for 15-30 minutes at 37º C. 50μl of sulfuric acid solution was added and the optical density of each well determined using a micro plate reader set at 450nm

STATISTICAL ANALYSIS

Data was processed and stored in Microsoft Access 2000. Minitab version 17 was used for all statistical analysis. Descriptive statistics were established and the values were expressed as mean ± standard deviation (SD). Data from patients and controls were compared using the 2 sample t-test. Simple linear regression analysis was used to find the relationship between CAII, gender and hematological parameters in children with clinical complications of SCD. P-values ≤ 0.05 were considered as indicating statistical significance.

RESULTS

Demographic information of the sampled population

In this study, a total of 40 children were recruited. The children’s ages, gender and the sickle cell status were established. The participants were placed in two groups, which were 20 children with SCD and 20 healthy controls. Table 1 shows that equal number of males (14 males) and females (6 females) from both the children with SCD and control group were sampled. In the sampling of the children with SCD, 16 children had clinical complications defined as stroke, anemia, infection, abdominal pain, priapism and pain crisis and 4 children had observable complications. The results showed that the mean age of male children with sickle cell disease was 7.28 years while for the female with SCD was 8.80 years. In the control group, the average age of the males was 4.94 years and that of the female was 5.17 years.

Hematological parameters

Table 3 shows that, levels of RBC, Hgb and HCT were significantly higher in healthy controls than children with SCD. The levels of WBC, Plts and MCV were significantly higher in children with SCD than in healthy controls. However, there was no significant difference in the levels of MCH and MCHC in both the groups. All the individuals with SCD screened were of the homozygous state Hb SS. This was characterized by raised HbS with a mean of 93.7 ± 5.91 and also elevated HbF of 2.6 ± 6.42. The HbA? was moderately elevated (3.7 ± 3.5) as compared to the healthy controls. All healthy controls had normal hemoglobin HbAA with the percentage of HbA° in all the samples represented as 95.5 ± 2.9, while the average percentage of HbA2 was 3.19 ± 0.32 and HbF 1.31 ± 1.6 as shown in Table 2.

Carbonic anhydrase II levels

Sickle cell disease children had a significantly higher mean CAII levels than healthy controls (116.4 ± 50.03ng/ml vs 77.6 ± 42.29ng/ml, p=0.0001) (Table 3).

Correlation between erythrocyte carbonic anhydrase II and the hematological parameters

There was an inverse association with hemoglobin and MCV in children with SCD compared to the control group (Table 4).

Carbonic anhydrase II levels in relation to Gender

There was no significant difference in the mean levels of CAII recording according to gender in the cases (118.3 ± 51.1 vs 111.9 ± 48.5ng/ml p=0.652) while in the control group a significant difference in the mean levels of CAII with gender (87.8 vs 55.2ng/ ml p=0.0001) was observed (Table 5).

Carbonic anhydrase in relation to clinical complications of sickle cell disease

Carbonic anhydrase II concentration was significantly enhanced in sicklers who suffered from clinical complications compared to sicklers who did not suffer from any clinical complications (126.2 ± 51.3 vs 79.8ng/ml, p=0.0001) (Table 6).

Relationship between carbonic anhydrase, hematological parameters and gender in children with clinical complications of sickle cell disease

Simple linear regression analysis showed a significant strong positive relationship between gender, CAII and the clinical complications of sickle cell disease (r=0.808, p=0.0001). Relationship between carbonic anhydrase II, hematological parameters and gender in children with clinical complications of sickle cell disease (r=0.808, r²=0.653, p=0.0001) is shown in Table 7 and 8.

Table 1: Demographic information of the participants.

Demography   SCD(n=20)   Controls(n=20)
Gender Number Percentage Number Percentage
Male  14   70   14   70
Female   6   30    6   30
Ages(Years) Male Female Male Female
Mean ±SD 7.28±1.08 8.80±1.88 4.94±1.10 5.17±0.41
Complications   13    3    
No complications    1    3    
SCD: Sickle Cell Disease; SD: Sandard Deviation; n: Number of Patients

Table 2: Hemoglobin Electrophoresis.

  HbA% HbA2% HbF% HbS%
Variables Mean±SD Mean±SD Mean±SD Mean±SD
Children with SCD   - 3.7±3.46 2.6±6.42 93.7±5.91
Healthy controls 95.5±2.9 3.19±0.32 1.31±1.6  
Hb: Hemoglobin; HbA: Hemoglobin Adult; HbF: Hemoglobin Fetal; HbS: Hemoglobin Sickle; SD: Standard Deviation

Table 3: Mean values of hematological parameters.

Children with SCD Controls
Variables Mean ± SD Mean ± SD  t Mean ± SD
RBC 3.314±0.955 4.884 ± 0.477 6.69 0.0001*
Hgbg/dL 9.070±1.573 12.750±1.187 8.58 0.0001*
HCT % 27.29±5.11 37.665±3.341 7.60 0.0001*
MCV 85.25±15.65 77.285±3.996 -2.20 0.039*
MCH pg 33.40±2.222 26.125±1.140 -1.88 0.075
MCHC g/dL 33.40±2.222 33.335±1.947 -0.10 0.922
WBC 12.18±1.1 7.24±0.46 -4.04 0.0001*
Plts 533.0±206.5 382.3±73.0 -3.08 0.005*
SCD: Sickle Cell Disease; RBC: Red Blood Cell; Hgb: Hemoglobin; HCT; Hematocrits; MCV: Mean Cell Volume, MCH: Mean Cell Hemoglobin; MCHC: Mean Cell Hemoglobin Concentration; WBC: White Blood Cells; Plts- Platlets; *- significance at p≤0.05; t: 2 sample t test.

 

DISCUSSION

This study investigated CAII levels among children with SCD. The mean CAII level was found to be significantly higher in sickle cell patients than the control group (116.4 ± 50.03 vs 77.6 ± 42.29, p=0.0001). A correlation of CA activity with erythrocyte zinc content has been suggested in other studies with an increase in both zinc and carbonic anhydrase in some patients with chronic leukemia and sickle cell anemia noted [12]. High levels of CA activity in sickle cell patients have also observed by [10,12]. However, this did not provide evidence for the cellular expression or location of CA in the erythrocyte membrane.

Since peripheral mature non-nucleated erythrocytes apparently do not synthesize CA [15], increased CAII could have occurred only when young cells were produced to compensate for the decrease of CAI and/or decrease of band 3 protein concentration. Chiang [16], suggested that G6PDH-deficient patients suffered from hemolytic anemia hence had a high population of young erythrocytes which synthesized CAI at a slower rate compared to hemoglobin and further suggested that increased CAII compensated for decreased expression of CAI and decreased band 3 proteins. Increased CAII could have also resulted from surface expression (decryption) rather than an increase in CAII synthesis. Possibly CAII on the inner leaflet of the red blood cell or the cytoplasmic domain of band 3 was translocated to the outer leaflet exposing the previously hidden enzyme [17,18].

According to this study red blood cell indices were generally low among the children with SCD compared to healthy controls with hemoglobin phenotype AA. Similar finding were obtained by [19], who found low red blood cell indices in the cases compared to the controls. High MCV levels were found in SCD patients in this study and were similar to the findings by Diop [20]. Sadarangani and Serjeant [21]. These findings suggested macrocytic anemia due to high level of MCV and could be attributed to the effect of anemia of chronic disease, infection and hemolysis as supported by Akinbami [2].

Though not significant, a correlation between CAII and the hematological findings indicated an inverse association between CAII, hemoglobin and MCV. An early study indicated an inverse relation between CA and the fall in hemoglobin and suggested that hemoglobin and CA were structurally discrete though functionally related [22]. These findings could have suggested increased CAII levels in children with anemia resulting from ongoing hemolysis. WBC demonstrated a parallel association with CAII. Association between CAII and WBC could have also suggested increased CAII in chronic hemolysis. The study indicated no significant difference in the levels of CA II between gender in the SCD group. However, a significant difference in the levels of carbonic anhydrase II between gender was observed in the control group. Though experimental studies have proved that both androgen and estrogen influence the production of CA II [23]. Sickle cell disease is known to affect both male and female equally with gender differences experienced in adulthood [24]. The findings suggested that gender did not alter CAII levels in children with sickle cell disease.

This study indicated a significant high level of CAII in children who suffered from clinical complications of sickle cell disease compared to children who did not suffer from clinical complications of sickle cell disease. It is well known that the erythrocyte membrane undergo perturbation under hypoxia induced sickling exposing the previously hidden band 3 peptides which are recognized by surface antigens [18]. This leads to premature destruction of erythrocytes hence hemolysis a hallmark of the clinical complication. Mohamed & Ronquist [25], confirmed the reduction of band 3 protein in sickle cell patients and related it to the degree of hemolysis and so the degree of anemia. Increased CAII has been linked to decreased CAI and decreased band three proteins in hemolytic anemia [16].

Band three is considered to play a central role in erythrocyte membrane skeletal stability [25]. Waugh [26], suggested that denatured hemoglobin associated tightly with the cytoplasmic domain of the predominantly spinning protein, Band 3 and that the functional and ultra-structural abnormalities of sickle cell may have in some way been related to the membrane structural change. Since CAII is one of the associated structures of band 3 membrane components [27], an abnormality in the band 3 due to conformational change in the erythrocyte membrane, or perturbation could have resulted in description of CAII during the clinical complications of sickle cell disease. A possibility was demonstrated by the movement of phosphatidyl serine from the inner leaflet to the outer leaflet of the RBC membrane [18]. The findings of this study suggested that increased CAII during clinical complications could have been due to a young cell population resulting from hemolysis or decryption of CAII.

 A strong significant positive relationship was obtained between gender, CAII and the clinical complication of sickle cell disease (r= 0.613, p= 0.018). Significantly high WBC, MCV with decreased HCT contributed to enhanced CAII levels in children with clinical complications of SCD. This was expected since sickled red blood cells have abnormal hemoglobin which is broken down at a faster rate than replacement (hemolysis). Low RBC has been associated with low hemoglobin and low hematocrit and could have been attributed to ongoing hemolysis [2]. Elevated WBC was expected in children with clinical complications since sickled RBC were unable to traverse the opening in the splenic cords and were phagocytosed and destroyed by macrophages [2]. The hematological findings suggested anemia due to ongoing hemolysis which contributed to enhance CAII due to the young population of RBC. Gender did not contribute significantly to high CAII in children with clinical complications of SCD and this could be attributed to the fact that sickle cell affected males and females equally [24].

Table 4: Association between CA II and the hematological parameters.

                  Children with SCD          Controls
Variables     r     p-value     r    p-value
WBC  0.011      0.934  -0.193     0.189
Plts  -0.109      0.408  -0.021     0.887
MCV  -0.170      0.193  0.257     0.077
Hb  -0.068      0.607  0.059     0.690
HCT  0.021      0.930  0.057     0.669
WBC: White Blood Cells; Plts: Platelets; MVC: Mean Cell Volume; Hb: Hemoglobin; HCT: Hematocrit; SCD: Sickle Cell Disease

Table 5: Carbonic anhydrase II concentrations in children with SCD and healthy controls.

Status Mean CA II   t p-value
Children with SCD 116.4±50.03 4.36 0.0001*
Healthy controls 77.6±42.29    
SCD: Sickle Cell Disease; CA: Carbonic Anhydrase; t: 2 sample t test, *- significance at p ≤ 0.05

Table 6: Carbonic anhydrase II in relation to gender.

Status Gender N  Mean±SD   t p-values
Children with SCD Male 14 118.3±51.1 0.46 0.652
  Female  6 111.9±48.5    
Healthy Controls Male 14 87.8±17.8 3.51 0.0001*
  Female  6 55.2±46.3    
SCD: Sickle Cell Disease; n: Number of Patients; T: 2 Sample T Test; *- Significance at P≤0.05

Table 7: Carbonic anhydrase II levels in children with and without the clinical complications.

Children with SCD  n Mean ± SD  t p-value
Complications 16 126.1 ± 51.3 5.06 0.0001*
No complications  4 79.8 ± 12.5    
SCD: Sickle Cell Disease; n: Number of patients; t: 2 sample t test, *- significance at p ≤ 0.05

Table 8: Relationship between carbonic anhydrase, hematological parameters and gender in children with clinical complications of sickle cell disease.

Variables p-value
Gender 0.333
WBC 0.021*
MCV 0.0001*
Hb 0.182
Plts 0.866
HCT  0.227
RBC 0.227
WBC: White Blood Cells, MCV: Mean Cell Volume, Hb: Hemoglobin; Plts: Platelets; HCT: Hematocrits; RBC: Red Blood Cells;*- Significance at P ≤ 0.05

 

CONCLUSION

Plasma CA II levels were significantly enhanced in children with sickle cell anemia. Gender did not influence CA II levels in SCD children. The mean carbonic anhydrase II levels were enhanced in children with clinical complications of sickle cell anemia compared with children without clinical complications.

LIMITATION OF THE STUDY

Due to financial constraints the study was carried out in one center with a small sample size therefore might not represent the entire population.

ACKNOWLEDGEMENTS

We thank the parents and staff of Gertrude’s children hospital and Kenyatta University for their help in this study.

REFERENCES

1. Ashley-Koch A, Yang Q, Olney RS. Sickle hemoglobin (Hb S) allele and sickle cell disease: a HuGE review. Am J Epidemiol. 2000; 151: 839- 845.

2. Akinbami A, Dosunmu A, Adediran A, Oshinaike O, Adebola P, Arogundade O. Haematological values in homozygous sickle cell disease in steady state and haemoglobin phenotypes AA controls in Lagos, Nigeria. BMC Res Notes. 2012; 5: 396.

3. Day S, Chismark E. The cognitive and academic impact of sickle cell disease. J School Nurs. 2006; 22: 330-335.

4. Esbaugh AJ, Tufts BL. Tribute to RG Boutilier: evidence of a high activity carbonic anhydrase isozyme in the red blood cells of an ancient vertebrate, the sea lamprey Petromyzon marinus. J Exp Biol. 2006; 209: 1169-1178.

5. Arthurs G, Sudhakar M. Carbon dioxide transport. Continuing Education in Anaesthesia. Crit Care Pain. 2005; 56: 207-210.

6. Tomlinson W, Jacob J. Studies of Sickle-Cell Formation in Normal Saline, Plasma, and Sera with Carbonic Anhydrase Inhibitors. J Lab Clin Med. 1945; 30: 107-111.

7. Hilkovitz G. Sickle-cell Disease: New Method of Treatment. Br Med J. 1957; 2: 266-269.

8. Henderson A, Crockett EJ, Wright CH. Effect of carbonic anhydrase inhibitors on the course of sickle-cell disease. AMA Arch Int Med. 1959; 104: 68-71.

9. Nishita T, Anezaki R, Matsunaga K, Orito K, Kasuya T, Sakanoue H, et al. Measurement of Carbonic Anhydrase I and II Isozymes in Feces as a Marker of Occult Blood in Horses with Intestinal Tract Bleeding. J Equine Sci. 2013; 24: 57.

10. Lewis HD, Altschule MD. Blood carbonic anhydrase activity in anemia, with a note on polycythemia vera. Blood. 1949; 4: 442-454.

11. Mondrup M, Anker N. Carbonic anhydrase isoenzyme B in erythrocytes of subjects with different types of anemia. Clinica Chimica Acta. 1976; 69: 463-469.

12. Vallee BL, Gibson JG. The zinc content of whole blood, plasma, leukocytes and erythrocytes in the anemias. Blood. 1949; 4: 455-466.

13. E Ariss AB, Younes M, Matar J, Berjaoui Z. Prevalence of Sickle Cell Trait in the Southern Suburb of Beirut, Lebanon. Med J Hematol Infec Dis. 2016; 8.

14. Kline JA, Zagorski J. Method of using carbonic anhydrase to detect hemolysis. 2011.

15. Hamasaki N. The role of band 3 protein in oxygen delivery by red blood cells. Ind J Clin Biochem. 1999; 14: 49-58.

16. Chiang WL, Chu SC, Lai JC, Yang SF, Chiou HL, Hsieh YS. Alternations in quantities and activities of erythrocyte cytosolic carbonic anhydrase isoenzymes in glucose-6-phosphate dehydrogenase-deficient individuals. Clinica Chimica Acta. 2001; 314: 195-201.

17. Frenette PS, Atweh GF. Sickle cell disease: old discoveries, new concepts, and future promise. J Clin Invest. 2007; 117: 850-858.

18. Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood. 1997; 89; 1121-1132.

19. Sadarangani M, Makani J, Komba AN, Ajala?Agbo T, Newton CR, Marsh K, et al. An observational study of children with sickle cell disease in Kilifi, Kenya. Br J Haematol. 2009; 146: 675-682.

20. Diop S, Thiam D, Cisse M, Toure-Fall A, Fall K, Diakhate L. New results in clinical severity of homozygous sickle cell anemia in Dakar, Senegal. Hematol Cell Ther. 1999; 41: 217-221.

21. Serjeant GR. The emerging understanding of sickle cell disease. Br J Haematol. 2001; 112: 3-18.

22. Vallee BL, Lewis HD, Altschule MD, Gibson JG. The relationship between carbonic anhydrase activity and zinc content of erythrocytes in normal, in anemic and other pathologic conditions. Blood. 1949; 4: 467-478.

23. Jeffery S, Carter ND, Wilson C. Carbonic anhydrase II isoenzyme in rat liver is under hormonal control. Biochem J. 1984; 221: 927-929.

24. Ilesanmi OO. Gender Differences in SCD Crises: Implications for Genetic Counselling and Psychotherapy. Int J Inform Educ Technol. 2014; 4: 215.

25. Mohamed AO, Ronquist G. Reduction in band 3 protein of red cells in sickle cell anaemia. Ups J Med Sci. 1991; 96: 23-33.

26. Waugh S, Willardson B, Kannan R, Labotka R, Low P. Heinz bodies induce clustering of band 3, glycophorin, and ankyrin in sickle cell erythrocytes. J Clin Invest. 1986; 78: 1155.

27. Vince JW, Reithmeier RA. Carbonic anhydrase II binds to the carboxyl terminus of human band 3, the erythrocyte Cl−/HCO3 − exchanger. J Biol Chem. 1998; 273: 28430-28437.

Midiwo C, Okun D, Gwer S, Ogweno G (2017) Plasma Carbonic Anhydrase II Level is Increased in Children with Sickle Cell Anaemia Compared to Healthy Controls. Arch Paediatr Dev Pathol 1(3): 1013.

Received : 10 Jul 2017
Accepted : 21 Jul 2017
Published : 24 Jul 2017
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X